The Experience with Cytotoxic Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

Research output: Contribution to journalReview articlepeer-review

Abstract

This article reviews the initial experience with chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) and outlines some of the ongoing clinical trials in this area. In addition, the authors outline current knowledge on outcomes of patients treated with taxane-based chemotherapy on retrospective analysis of randomized trials. These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials.

Original languageEnglish (US)
Pages (from-to)573-581
Number of pages9
JournalUrologic Clinics of North America
Volume39
Issue number4
DOIs
StatePublished - Nov 1 2012

Keywords

  • Cytotoxic chemotherapy
  • Docetaxel
  • Metastatic castration-resistant prostate cancer

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'The Experience with Cytotoxic Chemotherapy in Metastatic Castration-Resistant Prostate Cancer'. Together they form a unique fingerprint.

Cite this